(Q84511909)

English

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

scientific article published on 01 October 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733061%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733061%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

based on heuristic

inferred from title

type 2 diabetes

0 references

placebo-controlled trial

1 reference

based on heuristic

inferred from title

Per-Henrik Groop

4

object named as

P-H Groop

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21733061

6 December 2024

author name string

V. Lukashevich

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21733061

6 December 2024

A. Schweizer

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21733061

6 December 2024

Q. Shao

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21733061

6 December 2024

W. Kothny

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21733061

6 December 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21733061

6 December 2024

publication date

1 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733061%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

October 2011

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21733061

6 December 2024

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1463-1326.2011.01467.x

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2011.01467.x/fullpdf

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733061%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733061%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733061%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

947-954

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733061%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Management of glycemia in patients with diabetes mellitus and CKD.

2

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus

4

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

5

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

6

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

7

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

8

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

9

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

10

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

11

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

12

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study

13

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

14

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study

15

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

16

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

17

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

18

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy

19

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Management of diabetes in dialysis patients

20

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

21

1 reference

10.1111/J.1463-1326.2011.01467.X

https://api.crossref.org/works/10.1111/J.1463-1326.2011.01467.X

6 December 2024

Identifiers

10.1111/J.1463-1326.2011.01467.X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733061%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21733061%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84511909&oldid=2284056622"